EA201391725A1 - Способ лечения немелкоклеточного рака легкого - Google Patents
Способ лечения немелкоклеточного рака легкогоInfo
- Publication number
- EA201391725A1 EA201391725A1 EA201391725A EA201391725A EA201391725A1 EA 201391725 A1 EA201391725 A1 EA 201391725A1 EA 201391725 A EA201391725 A EA 201391725A EA 201391725 A EA201391725 A EA 201391725A EA 201391725 A1 EA201391725 A1 EA 201391725A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lung cancer
- nucleotides
- little
- treatment
- cell lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Способ лечения больного человека, страдающего раком легкого, включающий периодическое введение больному человеку химиотерапевтических средств, содержащих количество таксана и 640 мг олигонуклеотида против кластерина с последовательностью CAGCAGCAGAGTCTTCATCAT (SEQ ID NO:1), где олигонуклеотид против кластерина имеет на всем протяжении фосфоротиоатный остов, имеет части сахаров нуклеотидов 1-4 и 18-21, несущие 2'-О-метоксиэтильные модификации, имеет нуклеотиды 5-17, которые представляют собой 2'-дезоксинуклеотиды, и имеет 5-метилцитозины в нуклеотидах 1, 4 и 19, в результате чего осуществляется лечение больного человека, страдающего раком легкого.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161487918P | 2011-05-19 | 2011-05-19 | |
US201161493346P | 2011-06-03 | 2011-06-03 | |
PCT/IB2012/001085 WO2012156817A2 (en) | 2011-05-19 | 2012-05-18 | Method for treating non-small cell lung cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201391725A1 true EA201391725A1 (ru) | 2014-05-30 |
Family
ID=47177396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391725A EA201391725A1 (ru) | 2011-05-19 | 2012-05-18 | Способ лечения немелкоклеточного рака легкого |
Country Status (16)
Country | Link |
---|---|
US (1) | US20130017272A1 (ru) |
EP (1) | EP2709673A4 (ru) |
JP (1) | JP2014520081A (ru) |
KR (1) | KR20140034838A (ru) |
CN (1) | CN103958681A (ru) |
AR (1) | AR086514A1 (ru) |
AU (1) | AU2012257487A1 (ru) |
CA (1) | CA2836676A1 (ru) |
CL (1) | CL2013003324A1 (ru) |
EA (1) | EA201391725A1 (ru) |
IL (1) | IL227720A0 (ru) |
MX (1) | MX2013013384A (ru) |
PE (1) | PE20140647A1 (ru) |
SG (1) | SG194931A1 (ru) |
WO (1) | WO2012156817A2 (ru) |
ZA (1) | ZA201309254B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU767133B2 (en) | 1999-02-26 | 2003-10-30 | University Of British Columbia, The | TRPM-2 antisense therapy |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
KR20140038388A (ko) | 2011-03-15 | 2014-03-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용 |
UY34812A (es) * | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
CA2900533A1 (en) * | 2013-03-14 | 2014-10-02 | Oncogenex Technologies Inc. | Anti-clusterin monotherapy for cancer treatment |
CA2903239A1 (en) * | 2013-03-14 | 2014-10-02 | Oncogenex Technologies Inc. | Custirsen treatment with reduced toxicity |
US20160324439A1 (en) * | 2015-05-06 | 2016-11-10 | Taiwan Textile Research Institute | Stereoscopic conductive fabric and module for detecting electrical signals from body skin applying the same |
WO2016191751A1 (en) * | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
EP3302502B1 (en) * | 2015-05-29 | 2019-08-28 | Dynavax Technologies Corporation | Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung |
KR20190115505A (ko) | 2018-03-15 | 2019-10-14 | 특허법인 해담 | 기업 맞춤형 후속 개발 아이템 발굴 방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
WO2003062421A1 (en) * | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
EP1789460B1 (en) * | 2004-09-02 | 2013-01-09 | Isis Pharmaceuticals, Inc. | Polymeric beads for oligonucleotide synthesis |
-
2012
- 2012-05-18 KR KR1020137033743A patent/KR20140034838A/ko not_active Application Discontinuation
- 2012-05-18 PE PE2013002522A patent/PE20140647A1/es not_active Application Discontinuation
- 2012-05-18 CA CA2836676A patent/CA2836676A1/en not_active Abandoned
- 2012-05-18 MX MX2013013384A patent/MX2013013384A/es not_active Application Discontinuation
- 2012-05-18 WO PCT/IB2012/001085 patent/WO2012156817A2/en active Application Filing
- 2012-05-18 JP JP2014510898A patent/JP2014520081A/ja active Pending
- 2012-05-18 EA EA201391725A patent/EA201391725A1/ru unknown
- 2012-05-18 SG SG2013083951A patent/SG194931A1/en unknown
- 2012-05-18 AU AU2012257487A patent/AU2012257487A1/en not_active Abandoned
- 2012-05-18 CN CN201280030054.1A patent/CN103958681A/zh active Pending
- 2012-05-18 US US13/475,780 patent/US20130017272A1/en not_active Abandoned
- 2012-05-18 EP EP12786050.0A patent/EP2709673A4/en not_active Withdrawn
- 2012-05-21 AR ARP120101802A patent/AR086514A1/es not_active Application Discontinuation
-
2013
- 2013-09-16 IL IL227720A patent/IL227720A0/en unknown
- 2013-11-19 CL CL2013003324A patent/CL2013003324A1/es unknown
- 2013-12-09 ZA ZA2013/09254A patent/ZA201309254B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2013013384A (es) | 2014-06-11 |
KR20140034838A (ko) | 2014-03-20 |
CN103958681A (zh) | 2014-07-30 |
EP2709673A2 (en) | 2014-03-26 |
AR086514A1 (es) | 2013-12-18 |
CL2013003324A1 (es) | 2014-08-01 |
AU2012257487A1 (en) | 2014-01-16 |
JP2014520081A (ja) | 2014-08-21 |
CA2836676A1 (en) | 2012-11-22 |
ZA201309254B (en) | 2015-05-27 |
SG194931A1 (en) | 2013-12-30 |
EP2709673A4 (en) | 2014-12-17 |
WO2012156817A3 (en) | 2013-02-21 |
PE20140647A1 (es) | 2014-06-05 |
US20130017272A1 (en) | 2013-01-17 |
WO2012156817A2 (en) | 2012-11-22 |
IL227720A0 (en) | 2013-09-30 |
WO2012156817A9 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201391725A1 (ru) | Способ лечения немелкоклеточного рака легкого | |
PH12014502569A1 (en) | Method for treating non-small cell lung cancer | |
US10184151B2 (en) | Micrornas in neurodegenerative disorders | |
NZ630914A (en) | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation | |
MX2013009191A (es) | Oligonucleotidos antisentido. | |
JP2013529909A5 (ru) | ||
RU2014101547A (ru) | Апоптоз-индуцирующее средство | |
RU2013148024A (ru) | Композиции и способы ингибирования экспрессии гена tmprss6 | |
MX2018012038A (es) | Agentes de iarn modificados. | |
EA201490563A1 (ru) | Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера | |
EA202090338A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
JP2015514778A5 (ru) | ||
TN2015000079A1 (en) | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies | |
RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
NZ700902A (en) | Lowering saturated fatty acid content of plant seeds | |
WO2013088338A1 (en) | Micrornas and uses therof | |
NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
RU2013121802A (ru) | Профилактический или терапевтический агент для лечения фиброза | |
AR091327A1 (es) | DISEÑO DE ARNhc BIFUNCIONAL EN EL SARCOMA DE EWING | |
RU2016131028A (ru) | Композиции, содержащие асимметричную интерферирующую рнк, которые подвергают сайленсингу k-ras, и способы их применения | |
WO2011087343A3 (ko) | Hpv 감염과 관련된 암의 치료용 조성물 | |
WO2012131673A3 (en) | Ccat-1 silencing nucleic acid agents for treating cancer | |
Philip et al. | Mechanistic role of let-7c in breast cancer cell activity | |
MX2008016104A (es) | Terapia génica mediante silenciamiento del gen wt1 con secuencias de rnas de interferencia a través de polietilenamina administrados via aerosol para cancer pulmonar. |